Article Information
History
- June 7, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- I Gentile1,
- A Giaccone2,*,
- MM Scirocco1,
- F Di Brizzi1,
- F Cuccurullo1,
- M Silvitelli1,
- L Ametrano1,
- FA Alfè1,
- D Pietroluongo1,
- I Irace1,
- MR Chiariello1,
- N De Felice1,
- S Severino1,
- G Viceconte1,
- N Schiano Moriello1,
- AE Maraolo1,
- AR Buonomo1,
- R Scotto1,
- Federico II COVID team°
- 1Department of Clinical Medicine and Surgery – Section of Infectious Diseases, University of Naples Federico II, Italy
- 2AORN Ospedali dei Colli, Cotugno Hospital, Department of Infectious Diseases, Unit of Geriatric Infectious Diseases, Naples, Italy
- ↵*Corresponding author
: Dr. Agnese Giaccone. AORN Ospedali dei Colli, Cotugno Hospital, Department of Infectious Diseases, Unit of Geriatric Infectious Diseases, Via G. Quagliarello 54, 80131, Naples, Italy Email: agnese.giaccone{at}ospedalideicolli.it Phone: +39 081 7067962
Posted June 07, 2024.
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)
